T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease

October 13, 2022

https://www.globenewswire.com/news-release/2022/10/13/2533963/32489/en/T2-Biosystems-Announces-Plan-to-Commercialize-a-Diagnostic-Test-for-Early-Lyme-Disease.html

LEXINGTON, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans to complete development of, and commercialize, a diagnostic test for the detection of early Lyme disease, with the goal of initiating marketing and sales in the United States as a Laboratory Developed Test (LDT) in 2023.

Read more at globenewswire.com

Related news for (TTOO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.